Anna Sawka

Dr. Anna Sawka


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
ASAnna Sawka
Anna Sawka
ANAsima Naeem
Asima Naeem
JJJennifer Jones
Jennifer Jones
JLJulia Lowe
Julia Lowe
PSPhilip Segal
Philip Segal
SEShereen Ezzat
Shereen Ezzat

24 May 2024 in Thyroid®
Verified
Journal Article
Open access
ASAnna Sawka
Anna Sawka
SGSangeet Ghai
Sangeet Ghai
LRLorne Rotstein
Lorne Rotstein
JIJonathan C. Irish
Jonathan C. Irish
JPJesse D. Pasternak
Jesse D. Pasternak
DGDavid Goldstein
David Goldstein
Background: It is important to understand cancer survivors' perceptions about their treatment decisions and quality of life. Methods: We performed a prospective observational cohort study of Canadian patients with small (<2 cm) low-risk papillary thyroid cancer (PTC) who were offered the choice of active surveillance (AS) or surgery ( Clinicaltrials.gov NCT03271892). Participants completed a questionnaire one year after their treatment decision. The primary intention-to-treat analysis compared the mean decision regret scale total score between patients who chose AS or surgery. A secondary analysis examined one-year decision regret score according to treatment status. Secondary outcomes included quality of life, mood, fear of disease progression, and body image perception. We adjusted for age, sex, and follow-up duration in linear regression analyses. Results: The overall questionnaire response rate was 95.5% (191/200). The initial treatment choices of respondents were AS 79.1% (151/191) and surgery 20.9% (40/191). The mean age was 53 years (standard deviation [SD] 15 years) and 77% (147/191) were females. In the AS group, 7.3% (11/151) of patients crossed over to definitive treatment (two for disease progression) before the time of questionnaire completion. The mean level of decision regret did not differ significantly between patients who chose AS (mean 22.4, SD 13.9) or surgery (mean 20.9, SD 12.2) in crude ( p = 0.730) or adjusted ( p = 0.29) analyses. However, the adjusted level of decision regret was significantly higher in patients who initially chose AS and crossed over to surgery (beta coefficient 10.1 [confidence interval; CI 1.3–18.9], p = 0.02), compared with those remaining under AS. In secondary adjusted analyses, respondents who chose surgery reported that symptoms related to their cancer or its treatment interfered with life to a greater extent than those who chose AS ( p = 0.02), but there were no significant group differences in the levels of depression, anxiety, fear of disease progression, or overall body image perception. Conclusions: In this study of patients with small, low-risk PTC, the mean level of decision regret pertaining to the initial disease management choice was relatively low after one year and it did not differ significantly for respondents who chose AS or surgery.

6 July 2023 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
ASAnna Sawka
Anna Sawka
SGSangeet Ghai
Sangeet Ghai
LRLorne Rotstein
Lorne Rotstein
JIJonathan C. Irish
Jonathan C. Irish
JPJesse D. Pasternak
Jesse D. Pasternak
MKMark Korman
Mark Korman
Individuals diagnosed with thyroid cancer are known to experience distressing emotions, including shock, fear, and anxiety.1-3 Concerns expressed by patients with newly diagnosed low-risk papillary thyroid cancer (PTC) relate to the cancer and its associated future outcome uncertainty as well as the potential risks and consequences of its treatment (eg, thyroidectomy).4 It is important to fully understand the fears experienced by individuals newly diagnosed with thyroid cancer to inform supportive care strategies and patient counseling. This understanding may be more fully informed in considering the context of gender.

1 October 2025 in JAMA Surgery
Verified
Journal Article
Open access
ASAnna Sawka
Anna Sawka
SGSangeet Ghai
Sangeet Ghai
LRLorne Rotstein
Lorne Rotstein
JIJonathan C Irish
Jonathan C Irish
JPJesse D Pasternak
Jesse D Pasternak
CACanadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area)
Canadian Thyroid Cancer Active Surveillance Study Group (Greater Toronto Area)
Importance: In managing early-stage cancers, active surveillance (AS) may be preferentially favored by older individuals. In counseling patients, it is important to understand the durability of AS in the context of age.Objective: To evaluate the durability of AS in patients with small, low-risk papillary thyroid cancer (PTC) according to age at the time of choosing AS.Design, Setting, and Participants: This single-center, prospective, long-term follow-up cohort study was conducted at a tertiary care hospital in Toronto, Ontario, Canada. Adult patients with small, localized, low-risk PTC less than 2 cm in maximal diameter were enrolled between May 2016 and February 2021. The clinical outcome data were analyzed up to the time point of May 25, 2025, and final data analysis was performed in June 2025.Exposure: All patients were offered the choice of AS or thyroid surgery.Main Outcomes and Measures: The primary outcome was the overall rate of AS crossover to definitive treatment (treatment completed or recommended by an investigator) and the indications. Cumulative crossover incidence function curves were examined according to age, with death from other causes as the competing risk.Results: A total of 200 patients (155 patients under AS and 45 who had immediate surgery) were followed up for a median (IQR) duration of 71 (59-84) months. Overall mean (SD) age was 52.0 (14.9) years, and 153 patients (76.5%) were female. There were no observed thyroid cancer–related deaths or any distant metastatic disease. The overall crossover rate from AS was 23.9% (37/155; 32 completed treatment, 3 declined surgery for disease progression, and 2 awaiting treatment). Crossover reasons included disease progression (56.8% [21/37]), patient preference (40.5% [15/37]), and ultrasound imaging limitations precluding accurate tumor measurement under active surveillance (tumor border not clearly distinguishable from heterogeneous echotexture of the thyroid parenchyma in a patient with Hashimoto thyroiditis; 2.6% [1/37]). The 5-year age-stratified cumulative overall crossover incidence rates were 41.5% (95% CI, 25.6%-56.8%) in patients younger than 45 years, 20.9% (95% CI, 12.3%-31.1%) in those aged 45 to 64 years, and 5.1% (95% CI, 0.9%-15.2%) in those aged 65 years and older (P < .001).Conclusion and Relevance: This single-center Canadian cohort study found that AS is a durable long-term management strategy for small, low -risk PTC, particularly in older individuals. Older individuals may be less likely to cross over to surgery after choosing AS.

1 January 2014 in Journal of Otolaryngology - Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
MMMazin Merdad
Mazin Merdad
AEAntoine Eskander
Antoine Eskander
JAJohn De Almeida
John De Almeida
JFJeremy Freeman
Jeremy Freeman
LRLorne Rotstein
Lorne Rotstein
DGDavid Goldstein
David Goldstein
Introduction: The detection of papillary thyroid microcarcinoma (PTMC) is on the rise and its optimal management remains controversial. Our aim was to determine the current self-reported management of PTMC amongst Canadian otolaryngologist-head and neck surgeons (OHNS) and endocrinologists and to identify factors influencing their management decisions. Methods: A nine item web-based questionnaire was distributed to Canadian OHNS and endocrinologists. The three main domains were demographics, current management of PTMC scenarios, and factors influencing the decisions. Results: One hundred and thirteen OHNS and endocrinologists completed the survey. Respondents were closely divided between recommending hemithyroidectomy (47%) or total thyroidectomy (43%) for a newly diagnosed PTMC in a low risk patient. Observation was the preferred method for managing PTMC detected incidentally after hemithyroidectomy (76%). Respondents chose more aggressive treatment for male patients compared to female patients. A positive history of thyroid cancer or previous radiation exposure was the most important factor influencing the management of PTMC. Conclusion: The current practices of Canadian OHNS and endocrinologist largely coincide with available guidelines. The slight variation in practice might be explained by the opposing evidence supporting different management options. Given the dramatic increase in the incidence of PTMC we suggest future guidelines address the management of PTMC independently.

20 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ASAnna Sawka
Anna Sawka
SGSangeet Ghai
Sangeet Ghai
OIOgemdi Ihekire
Ogemdi Ihekire
Jennifer JonesJennifer Jones
Jennifer Jones
AGAmiram Gafni
Amiram Gafni
OGon behalf of the Canadian Thyroid Cancer Active Surveillance Study Group
on behalf of the Canadian Thyroid Cancer Active Surveillance Study Group
We describe our experience conducting a prospective observational cohort study on the management of small, low risk papillary thyroid cancer during the COVID-19 pandemic. Our study participants are given the choice of active surveillance (AS) or surgery, and those in the AS arm are followed at the study center, whereas surgical patients undergo usual care. During the pandemic we have transitioned from in-person research patient visits to largely virtual care of patients under AS. As of 30 October 2020, we had enrolled 181 patients enrolled in our study (including 25 during the pandemic), of which 92.3% (167/181) consented to telephone communication and 79.0% (143/181) consented to secure videoconferencing communication. Prior to the pandemic, 74.5% (117/157) of our patients chose AS over surgery, whereas during the pandemic, 96.0% (24/25) chose AS. Of the 133 study patients who were under AS within the timeframe from 12 March 2020, to 30 October 2020, the percentage of patients who missed appointments was 8.3% (11/133, for neck ultrasound and physician visits, respectively) and delayed appointments was 23.3% (31/133). This preliminary data suggests that prospective observational research on AS of thyroid cancer can safely continue during the pandemic.